

## PATIENT SELECTION DEVICE SELECTION VALVE SIZE SELECTION

Gerald Yong MBBS (Hons) FRACP FSCAI Interventional Cardiologist Royal Perth Hospital Western Australia

TAVI Summit 7<sup>th</sup> September 2012

### **Disclosure Statement of Financial Interest**

Within the past 12 months, I or my spouse/partner have had a financial Interest /arrangement or affiliation with the organization(s) listed below

<u>Affiliation/Financial Relationship</u> Grant/ Research Support:

**Consulting Fees/Honoraria:** 

Major Stock Shareholder/Equity Interest:

**Royalty Income:** 

**Ownership/Founder:** 

Salary:

**Intellectual Property Rights:** 


**Other Financial Benefit:** 

**Company** 


Edwards Lifesciences (consultant & proctor)


### Percutaneous Transcatheter Implantation of an Aortic Valve Prosthesis for Calcific Aortic Stenosis First Human Case Description

Alain Cribier, MD; Helene Eltchaninoff, MD; Assaf Bash, PhD; Nicolas Borenstein, MD; Christophe Tron, MD; Fabrice Bauer, MD; Genevieve Derumeaux, MD; Frederic Anselme, MD; François Laborde, MD; Martin B. Leon, MD




































## **PATIENT SELECTION**

## **PATIENT SELECTION**

### Indication

- Symptomatic severe aortic stenosis
- High risk for surgical AVR

### Suitable anatomy

- Other high risk clinical features to be aware
  Severe MR
  Severe LVF
  Irrevascularised CAD
  - Pulmonary hypertension

### Current TAVR Eligibility According to Operative Risk

% AVR Volume	75%	15%	10%	
Risk	Low Risk	Moderate Risk	High Risk Inoperable	
	STS <4%	4-8%	>8%	
TRIALS		PARTNER 2 SURTAVI	PARTNER 1A US CoreValve High Risk PARTNER 1B US CoreValve Extreme Risk	
IRRE	SPONSIBLE & RECKLESS	NEED DATA	REASONABLE	

SOURCE – Leon & Kodali

### **Other high risk features not included in Surgical Risk Scores**

- Porcelain aorta
- Chest deformity
- Chest irradiation
- Degenerative neurocognitive function
   Cirrhosis
- FRAILTY INDICES



# Frailty

Syndrome of multisystem impairment associated with aging that results in decreased physiologic reserve and increased vulnerability to stressors.



5m walk Get up and Go" test • Wt loss Grip strength Dependency on ADL score – Katz Serum albumin Serum hematocrit

### **The IDEAL TAVR Patient...**



## **ANATOMY ASSESSMENT**


## **Aortic Root Measurement**

Angiography with marker pigtailCT


Caution if

- Small aortic root (<30mm)</li>
- Short sinus height or distance to coronaries (<11mm)</p>
- Small STJ

## **Aortogram** With Marker Pigtail for calibration




## **Other Aortogram Issues...**




#### Vertical valve plane

#### **Unfolded aorta**

## Bulky Calcium in Aortic Valve





### **Peripheral Vessel Assessment**



## **DEVICE SELECTION**



#### **TAVR – Contemporary Results from Clinical Trials and Registries**

	PARTNER B	PARTNER A	SOURCE	Canadian	SOURCE XT	FRANCE 2	ADVANCE	CoreValve Meta- analysis
N & Valve type	Edwa <del>r</del> ds 179 TF	Edwards 244 TF 104 TA	Edwards 920 TF 1387 TA	Edwards 162 TF 177 TA	Edwards XT valve 2600	Edwards - 2017 CoreValve - 1043	CoreValve 1015	CoreValve 2156
Age	83.1	83.6	80.1	81.8	81.2	82.7	81	81.6
Logistic EuroScor e	26.4%	29.3%	26.1%	N/A	20.3%	21.9%	19.2	21.3%
30 day Mortality	5.0%	3.4%	9.5%	10.4%	6.2%	9.7%	4.5	6.6%
30 day Stroke	6.7%	5.5%	2.9%	2.3%	2.2%	4.1%	2.9	2.8%
1 year Mortality	30.7%	24.2%	23.5%	24%	N/A	24.0%	N/A	17.1%

Kodali, et al., *NEJM*; 2012;366:1686-95 ; Makkar, et al., *NEJM*, 2012;366:1696-704 ; Thomas, et al., *Circulation*, 2011;124:425-33 ; Rodes-Cabau, et al., *JACC*, 2010;55:1080-90 ; Gilard, et al., *NEJM*, 2012;366:1705-15 ; Wendler EuroPCR 2012 ; Ruiz EuroPCR 2011

### **TAVR – Contemporary Results from Clinical Trials and Registries**


	PARTNER B	PARTNER A	SOURCE	Canadian	SOURCE XT	FRANCE 2	ADVANCE	CoreValve Meta- analysis
N & Valve type	Edwards 179 TF	Edwards 244 TF 104 TA	Edwards 920 TF 1387 TA	Edwards 162 TF 177 TA	Edwards XT valve 2600	Edwards - 1145 CoreValve - 540	CoreValve 1015	CoreValve 2156
Major Vascular Cx	16.8%	11.0%	5.7%	13.0%	5.2%	12.5%	10.7%	4.2%
Bleeding	16.2%	9.3%	3.3%	N/A		18.4%	9.7%	N/A
РРМ	3.4%	3.8%	6.9%	4.9%	9.1%	12.4%	26.3%	28.7%








## Valve in Valve










## **DEVICE SIZING**


#### ORIGINAL ARTICLE

### Two-Year Outcomes after Transcatheter or Surgical Aortic-Valve Replacement

b Severity of Paravalvular Leak: None of Trace, Miliu, or Moderate



Kodali, et al., *NEJM*, 2012;366:1686-95



## **Predictors of Paravalvular Leak**


Malposition of valve

Degree and asymmetry of valve Ca


Undersizing of valve


Detaint et al. JACC Interv 2009;2:82107 Coli et al. Circulation 2009;120:S982 Delgado et al. Circulation 2009;120;S957 Willson, et al., JACC, 2012;59:1287-94 Jilaihawi, et al., JACC, 2012;59:1275-86

# Valve Sizing Dependent On Annulus Measure



## **Traditional Imaging for Annulus Sizing**






### **3-Dimensional Aortic Annular Assessment by Multidetector Computed Tomography Predicts Moderate or Severe Paravalvular Regurgitation After Transcatheter Aortic Valve Replacement**

A Multicenter Retrospective Analysis






109 patients underwent TAVI using Edwards SAPIEN valve

Valve size determination multifactorial


Retrospective analysis of MSCT and TOE assessment of annulus size

## **Predictor of PVL**



_		

тну тну			AUC	95% CI
0.0 -	тн∖	THV diameter – mean diameter	0.81	0.68-0.88
0.0 0.2		THV area/annular area	0.80	0.65-0.90
		THV circumference/annular circumference	0.76	0.59-0.91
Figure 3	Area Under the Curves for Pred	THV diameter – TEE annulus diameter	0.70	0.51-0.88
MDCT mean diameter (0.81, 95% area (0.80, 95% CI: 0.65 to 0.90) (TEE) diameter (0.70, 95% CI: 0.5 tation; other abbreviations as in Fi		Female	0.62	0.50-0.77
		Age, yrs	0.59	0.50-0.72
		Annular eccentricity	0.58	0.46-0.75



## Valve Sizing by CT – Edwards Valve The "St Paul's CT Sizing Scale"

Annular Area (m	nm <sup>2</sup> ) THV	THV size (mm)			
23mm	26mm	29mm			
4.15cm <sup>2</sup>	5.31cm <sup>2</sup>	6.61cm <sup>2</sup>			
>660	Risko	f leak/embolisation with			
	29				
		Courtesy – A Willson &			

Courtesy – A Willson & J Leipzic

### Step 5: Device Size Selection Aortic Annulus Ranges

	Diameter Range (mm)	meter Range (mm) Perimeter Range (mm)	
23	18 - 20	56.5 - 62.8	254.5 - 314.2
26	20 - 23	62.8 - 72.3	314.2 - 415.5
29	23 - 27	72.3 - 84.8	415.5 - 572.6
31	26 - 29	81.7 - 91.1	530.9 - 660.5

Recent evidence supports perimeter as the recommended method for TAVI sizing



INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve<sup>®</sup> is approved. Not for distribution in U.S., Canada or Japan. Medtronic, Inc. 2011. All Rights Reserved.



## Conclusion

- Proper patient selection and assessment is important to optimise outcome post TAVI
- No significant difference in outcomes between the commonly used valves in current registries
- Device sizing critically important. Improved device sizing, potentially by improved imaging modality, may reduce paravalvular leak and improve outcome and